Cynata Therapeutics

Gain a direct line to Cynata Therapeutics leadership

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Contact Us

Pre-Clinical Development

Clinical Development

Products & Pipeline

Scientific Publications

Intellectual Property

Cymerus™ Platform

Our technology

Board of Directors

About us

Company FAQs

Corporate Governance

Analyst Research

Investor FAQs

Financial Reports

Right to Receive Documents

Investor Presentations

Share Price

Announcements

Investors

Updates

Home

Frank Ruhl Libre

Read full article

The therapeutic potential of donor-derived mesenchymal stromal cells (MSCs) has been investigated in diverse diseases, including steroid-resistant acute graft versus host disease (SR-aGvHD). However, conventional manufacturing approaches are hampered by challenges with scalability and interdonor variability, and clinical trials have shown inconsistent outcomes. Induced pluripotent stem cells (iPSCs) have the potential to overcome these challenges, due to their capacity for multilineage differentiation and indefinite proliferation. Nonetheless, human clinical trials of iPSC-derived cells have not previously been completed. CYP-001 (iPSC-derived MSCs) is produced using an optimized, good manufacturing practice (GMP)-compliant manufacturing process. We conducted a phase 1, open-label clinical trial (no. NCT02923375) in subjects with SR-aGvHD. Sixteen subjects were screened and sequentially assigned to cohort A or cohort B (n = 8 per group). One subject in cohort B withdrew before receiving CYP-001 and was excluded from analysis. All other subjects received intravenous infusions of CYP-001 on days 0 and 7, at a dose level of either 1 × 10^6 cells per kg body weight, to a maximum of 1 × 10^8 cells per infusion (cohort A), or 2 × 10^6 cells per kg body weight, to a maximum dose of 2 × 10^8 cells per infusion (cohort B). The primary objective was to assess the safety and tolerability of CYP-001, while the secondary objectives were to evaluate efficacy based on the proportion of participants who showed a complete response (CR), overall response (OR) and overall survival (OS) by days 28/100. CYP-001 was safe and well tolerated. No serious adverse events were assessed as related to CYP-001. OR, CR and OS rates by day 100 were 86.7, 53.3 and 86.7%, respectively. The therapeutic application of iPSC-derived MSCs may now be explored in diverse inflammatory and immune-mediated diseases.

Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study